Rocket Pharmaceuticals, Inc. (9IP1.F)
| Previous close | 21.89 |
| Open | 19.57 |
| Bid | 19.56 x 0 |
| Ask | 20.36 x 0 |
| Day's range | 19.57 - 19.57 |
| 52-week range | 13.80 - 29.42 |
| Volume | |
| Avg. volume | 4 |
| Market cap | 1.777B |
| Beta (5Y monthly) | 1.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.66 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 69.78 |
ZacksWhy Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report?
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Simply Wall St.Rocket Pharmaceuticals (NASDAQ:RCKT) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Business WireRocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
CRANBURY, N.J., May 29, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Commission (EC), based on a positive opinion issued by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), has granted orphan medicinal product designation for RP-A601, the Company’s adeno-associated viru
